Publications

2024

Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.

JACC. Basic to translational science.9(7):865-876[DOI] 10.1016/j.jacbts.2024.03.003.[PMID] 39170956.

PubMed·Publisher's Site

2024

P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.

JACC. Cardiovascular interventions.17(11):1356-1370[DOI] 10.1016/j.jcin.2024.03.027.[PMID] 38597172.

3 citations·PubMed·Publisher's Site

2024

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.

Thrombosis and haemostasis.124(3):263-273[DOI] 10.1055/a-2098-6639.[PMID] 37224883.

2 citations·PubMed·Publisher's Site

2023

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.

JACC. Cardiovascular interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] 36317958.

10 citations·PubMed·Publisher's Site

2023

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.18(15):1254-1265[DOI] 10.4244/EIJ-D-22-00719.[PMID] 36602868.

8 citations·PubMed·Publisher's Site

2023

Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.

JACC. Cardiovascular interventions.16(20):2528-2539[DOI] 10.1016/j.jcin.2023.08.009.[PMID] 37609698.

2 citations·PubMed·Publisher's Site

2022

Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.

European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.

2 citations·PubMed·Publisher's Site

2022

Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.

Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.

6 citations·PubMed·Publisher's Site

2022

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.

European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.

6 citations·PubMed·Publisher's Site

2021

Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.

JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.

4 citations·PubMed·Publisher's Site

2020

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.

18 citations·PubMed·Publisher's Site

2020

Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.

Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.

9 citations·PubMed·Publisher's Site

2020

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.

Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.

18 citations·PubMed·Publisher's Site

2020

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.

JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.

24 citations·PubMed·Publisher's Site

2020

Vasospastic angina on coronary angiography.

BMJ case reports.13(9):-[DOI] 10.1136/bcr-2020-237753.[PMID] 32895257.

2 citations·PubMed·Publisher's Site

2019

Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.

JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.

26 citations·PubMed·Publisher's Site

2019

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.

12 citations·PubMed·Publisher's Site

2019

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.

101 citations·PubMed·Publisher's Site

2018

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.

Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.

43 citations·PubMed·Publisher's Site

2016

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.

97 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.

JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.

32 citations·PubMed·Publisher's Site

2015

Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.

JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.

65 citations·PubMed·Publisher's Site

2015

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.

4 citations·PubMed·Publisher's Site

2014

Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation.

JACC. Cardiovascular interventions.7(7):810-6[DOI] 10.1016/j.jcin.2013.11.026.[PMID] 24954573.

28 citations·PubMed·Publisher's Site

2013

Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions: a Randomized Evaluation

Journal of the American College of Cardiology.61():E1683-[DOI] .[PMID] .

PubMed·Publisher's Site

2012

Effects of Pioglitazone On Platelet P2Y12 Mediated Signaling in Clopidogrel Treated Patients With Type 2 Diabetes Mellitus

Journal of the American College of Cardiology.59():E263-[DOI] .[PMID] .

PubMed·Publisher's Site

2012

Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.

12 citations·PubMed·Publisher's Site

2012

Radial Access: Is There An Increased Risk of Operator Radiation Exposure During a Right Versus Left Radial Approach?

Journal of the American College of Cardiology.60():B117-[DOI] .[PMID] .

PubMed·Publisher's Site

2009

Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.73(1):1-14[DOI] 10.1002/ccd.21782.[PMID] 19089929.

28 citations·PubMed·Publisher's Site

2009

Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.

Best practice & research. Clinical endocrinology & metabolism.23(3):375-88[DOI] 10.1016/j.beem.2008.12.001.[PMID] 19520310.

43 citations·PubMed·Publisher's Site

2008

Prasugrel: a Novel Platelet Adp P2Y(12) Receptor Antagonist. a Review On Its Mechanism of Action and Clinical Development

Expert Opinion on Pharmacotherapy.9():2893-2900[DOI] 10.1517/14656560802450405.[PMID] .

PubMed·Publisher's Site

2008

Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.

Expert opinion on pharmacotherapy.9(16):2893-900[DOI] 10.1517/14656566.9.16.2893.[PMID] 18937620.

34 citations·PubMed·Publisher's Site

Show More